bioAffinity Technologies Sees Surge in CyPath Lung Test Sales Amid Nasdaq Compliance Concerns

bioAffinity Technologies has seen a 72% surge in sales of its CyPath Lung test in July, despite facing potential delisting from the Nasdaq Capital Market. The company plans to appeal the decision and is focusing on growth opportunities, including international patent approvals and successful product tests. Analyst rating is a Buy with a $6.00 price target, but technical indicators suggest stability in the short term, with significant financial challenges and Nasdaq compliance issues presenting notable risks.

BioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company specializing in noninvasive diagnostics and early cancer detection, reported a significant surge in sales of its flagship product, CyPath® Lung, in July 2025. The company saw a 72% increase in commercial sales compared to the previous monthly average for the first six months of 2025 [1].

Despite this positive growth, BioAffinity Technologies is currently facing potential delisting from the Nasdaq Capital Market. The company has indicated its intention to appeal the decision and is focusing on growth opportunities, including international patent approvals and successful product tests. Analysts have maintained a Buy rating for the stock with a $6.00 price target, but technical indicators suggest stability in the short term [2].

The surge in sales of CyPath® Lung is attributed to the product's ability to detect lung cancer at its earliest stage, as demonstrated by recent case studies. The company's President and CEO, Maria Zannes, noted that increasing awareness and trust in the technology are driving market momentum. The company also highlighted the growing demand from physicians, payers, and patients, positioning it for long-term revenue growth [1].

BioAffinity Technologies is expanding its market reach, particularly in the Mid-Atlantic region and the Veterans Administration healthcare system. The company's Chief Financial Officer, J. Michael Edwards, emphasized the success of the pilot marketing program in Texas, which has approximately 6% of the total number of U.S. pulmonologists. The program has demonstrated that the company's approach to the medical community is sound and effective [1].

The company's Chief Medical Officer, Gordon Downie, MD, PhD, underscored the importance of early detection in improving survival rates for lung cancer. He noted that CyPath® Lung can better inform shared decision-making between doctors and patients and ease anxiety about appropriate next steps [1].

Despite the challenges posed by the potential Nasdaq delisting and compliance issues, BioAffinity Technologies remains focused on its strategic growth plans. The company's recent financial transactions, including a private placement and warrant inducement transaction for approximately $1.2 million in gross proceeds, demonstrate its commitment to securing capital for continued expansion [2].

References:
[1] https://www.stocktitan.net/news/BIAF/bio-affinity-technologies-reports-accelerating-growth-in-cy-path-3t6k874gkcql.html
[2] https://www.morningstar.com/news/pr-newswire/20250813ny50746/wallachbeth-capital-announces-pricing-of-bioaffinity-technologies-private-placement-and-concurrent-warrant-inducement-transaction-for-approximately-12-million-in-gross-proceeds